News >

Tafasitamab/Lenalidomide Combo Application Fast-Tracked in Europe

Gina Columbus @ginacolumbusonc
Published: Friday, May 22, 2020

Peter Langmuir, MD, group vice president, Targeted Therapies, Incyte

Peter Langmuir, MD

The European Medicines Agency (EMA) has validated a Marketing Authorization (MAA) for the combination of tafasitamab and lenalidomide (Revlimid), followed by single-agent lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low-grade lymphoma, who are ineligible for autologous stem cell transplant.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x